Jeffrey Dierks - Jan 16, 2025 Form 4 Insider Report for Harmony Biosciences Holdings, Inc. (HRMY)

Role
CHIEF COMMERCIAL OFFICER
Signature
/s/ Christian Ulrich, Attorney-in-Fact
Stock symbol
HRMY
Transactions as of
Jan 16, 2025
Transactions value $
-$124,518
Form type
4
Date filed
1/21/2025, 08:44 PM
Previous filing
Jan 16, 2025
Next filing
Jan 28, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HRMY Common Stock Options Exercise $986K +29.5K $33.44 29.5K Jan 16, 2025 Direct
transaction HRMY Common Stock Sale -$1.1M -29.5K -100% $37.41 0 Jan 16, 2025 Direct F1, F2
transaction HRMY Common Stock Options Exercise $37.6K +1.12K $33.44 1.12K Jan 21, 2025 Direct
transaction HRMY Common Stock Sale -$44.9K -1.12K -100% $40.00 0 Jan 21, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HRMY Stock Option Options Exercise $0 -29.5K -81.39% $0.00 6.74K Jan 16, 2025 Common Stock 29.5K $33.44 Direct F3
transaction HRMY Stock Option Options Exercise $0 -1.12K -16.67% $0.00 5.62K Jan 21, 2025 Common Stock 1.12K $33.44 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.98. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The stock option shall vest with respect to 50% of the underlying shares on June 1, 2023 and with respect to the remaining shares, in twenty-four equal monthly installments beginning on July 1, 2023.